Just a few years since pioneering a Covid-19 vaccine, Moderna faces a hostile political environment and a looming patent ...

The United States led the world in developing the technology that beat the COVID-19 pandemic. Action from lawmakers may leave ...

We recently published a list of 10 Stocks To Trade Without Tariffs And Interest Rate Fears. In this article, we are going to ...

Moderna was dealt a significant blow in the patent battle over who owns the Covid-19 vaccine last week. In the U.S., the Cambridge drug and vaccine maker hit a roadblock when the Patent Trial and ...

USPTO Finds Claims Of Two Of Moderna’s mRNA Patents Unpatentable: What’s Next In The Vaccine Wars? Legal News and Analysis - ...

Before joining Moderna, Cronin spent close to 20 years at Ogilvy, working within its global healthcare department in ...

Vaccine makers Moderna Inc (NASDAQ:MRNA) and Novavax Inc (NASDAQ:NVAX) are facing selling pressure on Wednesday following reports suggesting the Trump administration will end support for Gavi.

Cronin has worked at Moderna since 2021, when she was brought on to market the biotech company’s COVID-19 vaccine.

Given the uncertainty around its top-line growth, short-term investors should exercise caution when investing in MRNA stock.

Just a few years since pioneering a Covid-19 vaccine, Moderna faces a hostile political environment and a looming patent problem. We recently compiled a list of the 12 Most Promising Biotech ...

Shares of vaccine-maker Moderna MRNA closed at $34.71 on Monday, close to their 52-week low of $29.25. Moderna is facing several headwinds, including the declining COVID-19 vaccine and the soft ...